» Articles » PMID: 31053156

Natural History of Fibrodysplasia Ossificans Progressiva: Cross-sectional Analysis of Annotated Baseline Phenotypes

Abstract

Background: Fibrodysplasia Ossificans Progressiva (FOP; OMIM#135100) is an ultra-rare, severely disabling genetic disease characterized by congenital malformation of the great toes and progressive heterotopic ossification (HO) in muscles, tendons, ligaments, fascia, and aponeuroses often preceded by painful, recurrent soft tissue swelling (flare-ups). The formation of HO leads to progressive disability, severe functional limitations in joint mobility, and to a shortened life-span. In this prospective natural history study, we describe the baseline, cross-sectional disease phenotype of 114 individuals with FOP.

Methods: All subjects underwent protocol-specified baseline assessments to determine their disease status. Cross-sectional analyses were performed using linear regression in which functional evaluations (Cumulative Analogue Joint Involvement Scale [CAJIS] and the FOP-Physical Function Questionnaire [FOP-PFQ]) and the burden of HO as measured by low-dose whole body CT (volume of HO and number of body regions with HO) were assessed.

Results: Findings from 114 subjects (age range 4 to 56 years) were evaluated. While subject age was significantly (p < 0.0001) correlated with increased CAJIS (r = 0.66) and FOP-PFQ scores (r = 0.41), the estimated mean increases per year (based on cross-sectional average changes over time) were small (0.47 units and 1.2%, respectively). There was also a significant (p < 0.0001) correlation between baseline age and HO volume (r = 0.56), with an estimated mean increase of 25,574 mm/year. There were significant (p < 0.0001) correlations between the objective assessment of HO volume and clinical assessments of CAJIS (r = 0.57) and FOP-PFQ (r = 0.52).

Conclusions: Based on the cross-sectional analysis of the baseline data, functional and physical disability as assessed by CAJIS and the FOP-PFQ increased over time. Although longitudinal data are not yet available, the cross-sectional analyses suggest that CAJIS and FOP-PFQ are not sensitive to detect substantial progression over a 1- to 2-year period. Future evaluation of longitudinal data will test this hypothesis. The statistically significant correlations between HO volume and the functional endpoints, and the estimated average annual increase in total HO volume, suggest that the formation of new HO will be measurable over the relative short-term course of a clinical trial, and represents an endpoint that is clinically meaningful to patients.

Trial Registration: This study ( NCT02322255 ) was first posted on 23 December, 2014.

Citing Articles

Early Detection for Better Patient Outcome: A Case Report on Two Patients Presenting With Fibrodysplasia Ossificans Progressiva at Tikur Anbessa Specialized Hospital, Ethiopia.

Haile A, Azale A, Ayana B Case Rep Orthop. 2025; 2025:2161762.

PMID: 39949349 PMC: 11824486. DOI: 10.1155/cro/2161762.


Palovarotene (Sohonos), a synthetic retinoid for reducing new heterotopic ossification in fibrodysplasia ossificans progressiva: history, present, and future.

Hsiao E, Pacifici M JBMR Plus. 2024; 9(1):ziae147.

PMID: 39677926 PMC: 11646086. DOI: 10.1093/jbmrpl/ziae147.


Performance of simplified methods for quantification of [F]NaF uptake in fibrodysplasia ossificans progressiva.

de Ruiter R, Botman E, Teunissen B, Lammertsma A, Boellaard R, Raijmakers P Front Nucl Med. 2024; 4:1406947.

PMID: 39381032 PMC: 11460293. DOI: 10.3389/fnume.2024.1406947.


Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial.

Keen R, Dahir K, McGinniss J, Sanchez R, Mellis S, Economides A J Bone Miner Res. 2024; 39(10):1486-1492.

PMID: 39216107 PMC: 11425702. DOI: 10.1093/jbmr/zjae140.


Long-term use of interleukin-1 inhibitors reduce flare activity in patients with fibrodysplasia ossificans progressiva.

Haviv R, Zeitlin L, Moshe V, Ziv A, Rabinowicz N, De Benedetti F Rheumatology (Oxford). 2024; 63(9):2597-2604.

PMID: 38733591 PMC: 11371373. DOI: 10.1093/rheumatology/keae255.


References
1.
Hays R, Bjorner J, Revicki D, Spritzer K, Cella D . Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual Life Res. 2009; 18(7):873-80. PMC: 2724630. DOI: 10.1007/s11136-009-9496-9. View

2.
Kaplan F, Al Mukaddam M, Pignolo R . Acute unilateral hip pain in fibrodysplasia ossificans progressiva (FOP). Bone. 2017; 109:115-119. DOI: 10.1016/j.bone.2017.08.009. View

3.
Kaplan F, Al Mukaddam M, Pignolo R . A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017; 101:123-128. DOI: 10.1016/j.bone.2017.04.015. View

4.
Connor J, Evans D . Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br. 1982; 64(1):76-83. DOI: 10.1302/0301-620X.64B1.7068725. View

5.
Zhang W, Zhang K, Song L, Pang J, Ma H, Shore E . The phenotype and genotype of fibrodysplasia ossificans progressiva in China: a report of 72 cases. Bone. 2013; 57(2):386-91. PMC: 3975922. DOI: 10.1016/j.bone.2013.09.002. View